DiaGenic uses a proprietary concept to measure unique disease-specific responses in the blood, focusing on Alzheimer's disease. They are a world leader in identifying gene expression signatures in blood and protect their technology through an extensive patent portfolio. DiaGenic is listed on the Oslo Stock Exchange.